Medical Research Council Acute Lymphoblastic Leukaemia Trial in Children UKALL R1

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN13327255

Enrollment

256

Registered

2002-08-19

Start date

1991-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukaemia (acute) Cancer Leukaemia

Interventions

INDUCTION THERAPY: All patients receive induction chemotherapy with allopurinol, dexamethasone, vincristine, aspariganase and etoposide plus intrathecal methotrexate, cystarabine and hydrocortisone.

Eligibility

Inclusion criteria

Inclusion criteria: 1. Children under the age of 25 years at original diagnosis with first relapse of ALL at any site from previous UKALL trials or pilot studies 2. Multiple relapsed patients are excluded 3. Patients with prior history of toxicity or organ damage such that completion of the protocol is felt unlikely at the outset are to be excluded 4. Patients with Central Nervous System (CNS) relapse must have had prior radiotherapy

Exclusion criteria

Exclusion criteria: Not provided at time of registration.

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration.	—

Secondary

Measure	Time frame
Not provided at time of registration.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026